Clinical Trial Update: PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of PD-1 antibody SHR-1210 in adults with relapsed or refractory classic Hodgkin's lymphoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Hodgkin Lymphoma, Adult | Phase 2 | Status: COMPLETED | Results posted: 2024-02-01